Q1 FY27 results: Revenue and profit decline year-on-year

Revenue DeclineResults View source PDF Explain this filing

ANTHEM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-1.8%Reaction day

₹794.00

prior close

₹750.60

announcement price

After-mkt

timing

Nifty Midcap 150market-1.1%-0.8% vs market

Pharmaceuticals & Biotechnology peers, median of 170sector · industry level-1.6%-0.3% vs sector

On the reaction day the stock moved 0.8 pts less than Nifty Midcap 150 and 0.3 pts less than its Pharmaceuticals & Biotechnology peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.8

10m

+1.4

15m

-0.4

30m

+0.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-1.8-1.1-0.8-1.6-0.3

Next day

-1.5-2.0+0.5-2.4+0.9

-3.1-2.1-1.0-2.4-0.7

-0.6-1.0+0.4-1.4+0.8

-1.3-1.0-0.2-2.4+1.1

-0.6-0.2-0.4-2.0+1.3

+2.0-0.1+2.2-1.8+3.8

15d

+10.8+1.5+9.3-0.4+11.1

+11.3+1.1+10.2-1.2+12.5

+12.2-1.7+13.9+0.2+12.1

+0.8-9.2+10.0-6.6+7.4

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals & Biotechnology peers, median of 170Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Anthem Biosciences Q1 FY27 standalone revenue fell to Rs 3,838.42 Mn from Rs 5,380.11 Mn YoY, down about 28.6%. Standalone profit dropped to Rs 1,020.09 Mn from Rs 1,483.40 Mn. Consolidated revenue was Rs 4,182.18 Mn (vs Rs 5,402.09 Mn) and consolidated profit was Rs 1,199.41 Mn (vs Rs 1,357.91 Mn). Auditor K.P. Rao and Co. gave an unmodified review opinion on both results. Company also allotted 16.7 lakh shares under ESOP Scheme 2024 during the quarter.

Likely market impact

Sharp YoY revenue and profit decline may weigh on stock sentiment despite clean audit opinion and continued profitability.